Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0IVZPH
ADC Name
B7H3-ADC-17
Synonyms
B7H3 ADC 17
   Click to Show/Hide
Organization
Suzhou Medilink Therapeutics Ltd.
Drug Status
Investigative
Indication
In total 4 Indication(s)
Astrocytoma [ICD11:2F36]
Investigative
Kidney cancer [ICD11:2C90-2C91]
Investigative
Melanoma [ICD11:2C30]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Structure
Antibody Name
Anti-B7H3 mAb 2E3-02
  Antibody Info 
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
B7H3-ADC-17 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 54.06
%
HT29 cells
Colon cancer
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 54.06% (Day 18) Positive CD276 expression (CD276 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model of HT29 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model HT-29 CDX model
In Vitro Model Colon cancer HT29 cells CVCL_A8EZ
References
Ref 1 Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.